Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines
Retrieved on:
Monday, September 27, 2021
Research, Technology, Other Technology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Biotechnology, News, Compliance, IBD, Inflammation, Degenerative disease, Therapy, Adalimumab, Colon, Cancer, Patient, Engineering, Marketing, CEO, Pharmacy, WeChat, Mab, Autoimmunity, Intract, GI, Extrapyramidal system, Technology, Conditional sentence, Forward-looking statement, Safety, Enzyme, Pharma, Intellectual property, Neutralizing antibody, Protein, Pharmaceutical industry, Vaccine, Bio-Thera Solutions, Ltd., Intract Pharma, BIO-THERA SOLUTIONS, LTD., INTRACT PHARMA
Bio-Thera Solutions, Ltd. (688177.SH, Bio-Thera) and Intract Pharma (Intract) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intracts Soteria and Phloral drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.
Key Points:
- Bio-Thera Solutions, Ltd. (688177.SH, Bio-Thera) and Intract Pharma (Intract) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intracts Soteria and Phloral drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.
- Under the terms of the agreement, Intract has granted Bio-Thera a worldwide license to Intracts oral biologics drug delivery platform for a single undisclosed mAb product.
- Intract will receive an undisclosed upfront payment, with potential development and commercial milestone payments along with royalties on product sales.
- Intracts oral biologics delivery platform includes Soteria a technology which protects proteins such as mAbs from degradation in the intestinal lumen.